September 23, 2008
Rx100 Rescues Life If Administered ~26 Hours After Exposure to Lethal, Whole-Body Radiation!
JOHNSON CITY, Tenn., Sept. 23 /PRNewswire/ -- Studies conducted to date have demonstrated that even though a single, subcutaneous dose of Rx100 is administered some 26 hours after exposure to lethal, whole-body radiation, a relatively high percentage of test animals survive having received no support other than normal food and water (NOTE: Test animals in many survival protocols receive additional supportive care in the form of antibiotics, etc.). "Preliminary studies suggest a wider time window may well be achievable," stated RxBio Chairman and CEO Dr. W. Shannon McCool.
In addition, an enhancement of total white blood cell and platelet counts in peripheral blood and significant increase of crypt regeneration in the small intestine has been observed following treatment with Rx100. Pharmacokinetic studies have revealed that Rx100 has a long serum half-life.
Rx100 is unique as a radioprotectant / radiomitigator in that it can be administered orally or by subcutaneous injection and it possesses a variety of favorable product characteristics that make it an ideal agent for use as a radiation countermeasure.
Rx100 is a potent radiomitigator that also ameliorates radiation- associated hematopoietic syndrome as well as gastrointestinal syndrome.
CONTACT: W. Shannon McCool, D.Ph., RxBio, Inc., +1-423-928-3330; fax:+1-423-282-6602, [email protected]
Web site: http://www.rxbio.com/